GIP and GLP-1 in Type 1 Diabetes

Mikkel Christensen

Status: Completed

Conditions: Hypoglycemia

Treatments: Other: GLP-1; Other: Saline; Other: GIP

Study type: Interventional

Funder types: Other

Identifiers

NCT01739283

H-2-2009-078 33269

Details and patient eligibility

About

Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and hypoglycemia in type 1 diabetes.

Enrollment: 10 patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with type 1 diabetes (WHO criteria)

Exclusion criteria

• HbA1c > 9 %
• Liver disease (ALAT/ASAT > 2 x upper normal limit)
• Diabetic nephropathy (s-creatinine > 130 µM or albuminuria)
• Proliferative diabetic retinopathy (anamnestic)
• Severe arteriosclerosis or heart failure (NYHA group III or IV)
• Anemia
• treatment with medication not applicable to pause for 12 hours
• C-peptide increase after 50 g iv arginine

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

10 participants in 2 patient groups

hyperglycemia

Experimental group

Description:

Hyperglycemic clamping

Treatment:

Other: Saline

Other: GIP

hypoglycemia

Experimental group

Description:

Hypoglycemic clamping

Treatment:

Other: GLP-1

Other: Saline

Other: GIP